Compare Hilton Hotels Corporation Common Stock (HLT) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Illumina, Inc. — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.19 (market cap $72.76B), while Illumina, Inc. trades at $265 (market cap $39.95B). The key difference: Hilton Hotels Corporation Common Stock is the larger of the two by market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Illumina, Inc. for 83 Days on average.
| HLT | ILMN | |
|---|---|---|
Market Cap | $72.76B | $39.95B |
Volume | 1,148,634 | 3,169,503 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $293.69 |
52-Week Low | $256.96 | $91.00 |
Typical Hold Time | 138 Days | 83 Days |
Enterprise Value | $85.78B | $41.31B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $320.50, down 0.65% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates consistent revenue growth, reaching $12.04 billion in 2025, with earnings beating expectations for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with 57% buy ratings and a $348.11 consensus price target representing 8.6% upside potential. Recent institutional buying activity and upcoming Q3 2026 earnings on October 27 provide near-term catalysts.
Hilton presents a compelling investment case with robust fundamentals and positive momentum, though elevated valuation metrics (P/E of 47.07) and increasing debt levels warrant caution. The stock's technical positioning near key support at $318 suggests potential for continued upward movement if earnings momentum persists, while institutional accumulation and strong travel demand support the bullish thesis.
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
